Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug de…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | ||
Eupraxia Pharmaceuticals Q1 Loss Narrows Eupraxia Pharmaceuticals' (EPRX.TO) first-quarter loss narrowed, the company said after trade on Tue | MMT Newswires | |
Eupraxia Reports Latest 36-Week Results From Resolve Trial Eupraxia Pharmaceuticals (EPRX.TO) Tuesday reported the latest 36-week results for the highest dose | MMT Newswires | |
 New Strong Sell Stocks for April 2nd ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026. | ||
Eupraxia Reports Positive Six-Month Data From Eosinophilic Esophagitis Trial Eupraxia Pharmaceuticals (EPRX.TO) Tuesday reported "positive data" from patients in the two highest | MMT Newswires | |
Eupraxia Pharmaceuticals Q4 Loss Widens Eupraxia Pharmaceuticals (EPRX.TO) overnight Thursday reported a wider fourth-quarter net loss. T | MMT Newswires | |
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option Eupraxia Pharmaceuticals (EPRX.TO, EPRX) was at last look up 4% in late Friday afternoon trade in Ca | MMT Newswires | |
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering Eupraxia Pharmaceuticals (EPRX.TO, EPRX) on Thursday announced the pricing of its previously announc | MMT Newswires | |
 Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... | ||
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial Eupraxia Pharmaceuticals (EPRX.TO) was at last look up near 1.8% early Thursday after announcing "po | MMT Newswires | |